Search by drug, manufacturer, or indication

Displaying 991 - 1000 of 1165

Adempas (riociguat)

Status:

Negotiations were not pursued

Manufacturer:

Bayer Inc.

Indication:

Pulmonary Arterial Hypertension (WHO group 1)

Last updated January 31, 2017

Xgeva (denosumab)

Status:

Negotiations were not pursued

Manufacturer:

Amgen Canada Inc.

Indication:

Prevention of skeletal-related events due to bone metastases from breast cancer

Last updated January 31, 2017

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Metastatic Renal Cell Carcinoma

Last updated January 20, 2017

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Non-small Cell Lung Cancer

Last updated January 20, 2017

Opdivo (nivolumab)

Status:

Concluded with an LOI

Manufacturer:

Bristol Myers Squibb Canada Inc.

Indication:

Metastatic Melanoma

Last updated January 20, 2017

Zydelig (idelalisib)

Status:

Negotiations were not pursued

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

Follicular lymphoma, Relapsed or refractory

Last updated January 13, 2017

Blincyto (blinatumomab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Acute Lymphoblastic Leukemia (ALL)

Last updated January 9, 2017

Imbruvica (ibrutinib)

Status:

Negotiations were not pursued

Manufacturer:

Janssen Inc.

Indication:

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last updated December 23, 2016

Darzalex (Daratumumab)

Status:

Negotiations were not pursued

Manufacturer:

Janssen Inc.

Indication:

Multiple Myeloma

Last updated December 23, 2016

Humira (adalimumab)

Status:

Negotiations were not pursued

Manufacturer:

AbbVie Corporation

Indication:

Hidradenitis Suppurativa

Last updated December 22, 2016